Insulet Corp Stock Price, News & Analysis

Insulet (NASDAQ: PODD), a leader in tubeless insulin pump technology, will release its financial results for Q2 2024 on August 8, 2024, after the market closes. A conference call will follow at 4:30 p.m. ET, accessible via the Investor Relations section of the company's website or by phone. Insulet's flagship product, the Omnipod® platform, offers innovative insulin delivery solutions, including the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors for simplified diabetes management.

Insulet (NASDAQ: PODD) announced positive results from its SECURE-T2D pivotal trial at the ADA 84th Scientific Sessions. The trial, the largest and most diverse study of automated insulin delivery (AID) in type 2 diabetes, highlighted significant improvements with the Omnipod 5 system. The results showed a 0.8% reduction in HbA1c overall, with a 2.1% decrease for those with baseline HbA1c ≥9.0%. Time in range increased by 20%, and total daily insulin dose decreased by 23 U/day. There were no significant hypoglycemia risks. The study included 305 participants, with 24% Black and 22% Hispanic representation, aiming for FDA approval for use in type 2 diabetes by early 2025.

Insulet has announced the full commercial launch of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) in the UK and the Netherlands. This system, compatible with Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitors, is available for individuals aged two and older with type 1 diabetes. Omnipod 5 is the first tubeless automated insulin delivery system integrated with both leading CGM sensor brands. It offers proactive glucose control, is waterproof, and aims to provide ease of use with demonstrated clinical results such as lower A1c levels and improved time in range. Patrick Crannell, Insulet's Senior VP, highlights the system's ability to allow users to choose their preferred CGM sensor, potentially benefiting thousands more people with diabetes.

Professor Partha S. Kar from NHS England emphasized the system's capacity to significantly simplify diabetes management. Clinical results have shown strong performance in maintaining glucose levels within the desired range while minimizing hypoglycemia instances.

Insulet (NASDAQ: PODD), a leader in tubeless insulin pump technology, announced the launch of its Omnipod 5 Automated Insulin Delivery System in France, now available for people aged two and older and compatible with the Dexcom G6 CGM. The French National Authority for Health has granted reimbursement status for the system.

In the U.S., Insulet has commenced the full commercial launch of Omnipod 5 with Dexcom G7 integration, offering users a new Pod compatible with both Dexcom G6 and G7 sensors. Additionally, the Omnipod 5 App for iPhone has begun a market release, initially integrating with Dexcom G6, with future updates to include Dexcom G7 compatibility.

These milestones reflect Insulet's commitment to expanding access to its innovative diabetes management technology globally.

Insulet (NASDAQ: PODD) announced that its management will present at the Jefferies Global Healthcare Conference in New York City on June 6, 2024, at 9:00 a.m. ET. The presentation will be accessible via a live audio webcast on the company's investor relations site, with a replay available post-event.

Insulet is renowned for its Omnipod® product platform, a tubeless insulin pump technology aimed at simplifying life for people with diabetes. The Omnipod Insulin Management System offers up to three days of non-stop insulin delivery without needle handling. Their latest innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor and can be controlled via smartphone or the Omnipod 5 Controller. Insulet is also exploring the use of its Omnipod technology for non-insulin subcutaneous drug delivery.

Insulet (NASDAQ: PODD) reported a 23% year-over-year revenue increase in the first quarter of 2024, with total revenue reaching $441.7 million. The Company exceeded its guidance range due to revenue outperformance across all product lines. Gross margin increased to 69.5%, operating income rose to $56.9 million, and net income reached $51.5 million. Insulet also achieved strong new customer starts, expanded market share globally, and launched new products like Omnipod 5 integrated with Dexcom's G7 sensor. The company is raising its full-year revenue and operating margin guidance for 2024.

Insulet (NASDAQ: PODD) released its 2023 Sustainability Report highlighting achievements in environmental, social, and governance areas. The report focuses on product accessibility, responsible growth, affordability, resilient operations, and sustainable product innovation. Insulet reached 425,000 active global customers, expanded financial assistance programs, generated renewable energy, reduced waste, and enhanced product sustainability. The company conducted a comprehensive double materiality assessment to prioritize initiatives and ensure operational resilience.